Eli Lilly Q1 Earnings Review: GLP-1 Leadership Is Still Expanding, but Pricing and Foundayo Are the Next Tests

$Eli Lilly and Co (LLY.US)$ 's first-quarter 2026 results reinforced one clear message: the company remains the strongest large-cap pharma growth story in the GLP-1 cycle. Revenue rose 56% year over year to $19.8 billion, while non-GAAP EPS jumped 156% to $8.55. More importantly, management raised full-year guidance, signaling that demand for Mounjaro, Zepbound, and other new medicines is still running ahead of prior expectations.

The market reaction was positive because this was not just a headline beat. Lilly’s adjusted EPS of $8.55 was well above Street expectations, while revenue also topped consensus, helped by strong Mounjaro and Zepbound sales. The stock rose more than 6% in premarket trading following the release, reflecting investor confidence that Lilly’s obesity and diabetes franchise remains in expansion mode.

Key Financial Highlights

The strongest part of the quarter was volume. Lilly said total revenue growth was driven by a 65% increase in volume, partly offset by a 13% decline from lower realized prices. This is the core tension in the report: demand is excellent, but pricing pressure remains a visible headwind, especially for Mounjaro and Zepbound.

GLP-1 Remains the Engine

The quarter was led by the tirzepatide franchise. Mounjaro revenue rose 125% to $8.7 billion, while Zepbound revenue rose 80% to $4.2 billion. Together, these two products generated nearly $12.8 billion in quarterly sales, representing the center of Lilly’s growth story.

This matters because Lilly is not only riding market growth; it is gaining share. In the U.S. incretin analog market, Lilly reported 60.1% share, versus 39.4% for $Novo-Nordisk A/S (NVO.US)$ . Internationally, Lilly also moved ahead with 53.2% share, versus Novo at 46.8%. That is an important competitive signal: Novo remains a powerful competitor, but Lilly is increasingly setting the pace in both U.S. and international GLP-1 markets.

Guidance Raise Confirms Management Confidence

Lilly raised its 2026 revenue guidance from $80B–$83B to $82B–$85B. Non-GAAP EPS guidance was also lifted from $33.50–$35.00 to $35.50–$37.00, while performance margin guidance increased to 47.0%–48.5%.

This is one of the most important takeaways from the report. A beat alone would have confirmed strong Q1 demand. A beat and raise suggests management sees enough durability in the current growth trajectory to lift the full-year outlook.

Foundayo Adds a New Growth Layer

The quarter also marked an important milestone for Lilly’s oral GLP-1 strategy. Foundayo is now launched in the U.S. for obesity, with retail availability beginning on April 9. Lilly said more than 12 major telehealth platforms are offering the drug, accounting for about 35% of launch volume, and that more than 80% of Foundayo prescriptions are from new incretin patients.

This is important because Foundayo could expand the GLP-1 market beyond injectable users. But investors should not treat the oral opportunity as fully proven yet. The next key questions are access, adherence, payer coverage, and whether Foundayo can compete effectively against Novo’s oral obesity strategy.

Pipeline Momentum Is Broadening

Lilly also delivered progress outside the core GLP-1 commercial franchise. The company highlighted positive Phase 3 data for Foundayo, retatrutide, Jaypirca, and Taltz plus Zepbound, while also announcing acquisitions of Orna Therapeutics, Centessa, Kelonia, and Ajax.

For investors, this matters because Lilly’s valuation depends on more than Mounjaro and Zepbound. Retatrutide, Foundayo, Jaypirca, Ebglyss, and the company’s expanding cardiometabolic pipeline are all part of the next growth layer. If these assets continue to deliver, Lilly can defend its premium multiple even as GLP-1 competition intensifies.

What Investors Should Watch Next

The first watch point is pricing. Lilly’s growth is still volume-led, but lower realized prices are already visible in both U.S. and international results. If price erosion accelerates, the market may start to question how much of the GLP-1 opportunity will convert into durable margin expansion.

The second watch point is Foundayo uptake. Early access through telehealth and retail channels is encouraging, but investors need to see whether prescriptions can scale beyond early adopters and whether payer access improves meaningfully.

The third watch point is Novo competition. Lilly’s reported share gains are impressive, but Novo remains a global GLP-1 incumbent with strong brand recognition and oral obesity exposure. The next stage of competition will likely be fought across dosing convenience, access, pricing, and long-term outcomes data.

The fourth watch point is pipeline execution. Retatrutide and Foundayo are especially important because they could extend Lilly’s cardiometabolic leadership beyond today’s tirzepatide franchise.

Bottom Line

Lilly delivered the type of quarter investors wanted: strong revenue growth, major EPS upside, leadership in GLP-1 share, and a full-year guidance raise. The company remains one of the clearest growth stories in global pharma.

The debate now shifts from “Can Lilly grow?” to “How durable is this growth?” For the stock to keep working, investors will need continued tirzepatide momentum, manageable pricing pressure, real Foundayo adoption, and steady pipeline execution. In short: Q1 confirmed Lilly’s leadership, but the next phase will test whether that leadership can translate into long-term margin and earnings durability.

107K Views